At 25.8% CAGR Cell and Gene Therapy Market Size to Reach $28.05 Billion By 2031
Cell Therapy Held Larger Share in Cell and Gene Therapy Market in 2023, full analysis by Product, Application, Source, Manufacturing, and Geography. NEW YORK, Oct. 30, 2024 /PRNewswire/ -- According to a new market research by The Insight Partners, the Global Cell and...
AbbVie to Acquire Aliada Therapeutics for $1.4B
AbbVie entered a definitive agreement to acquire Aliada, a biotechnology company developing therapies using a novel blood-brain barrier (BBB)-crossing technology for central nervous system (CNS) diseases, for $1.4 billion in cash. This transaction is expected to close...
Iowa resident dies of rare Lassa fever, officials say
The current risk of Lassa virus transmission in the US is "incredibly low," Iowa's medical director says. CS Goldsmith, P. Rollin, M. Bowen/CDCA resident of eastern Iowa who had recently traveled to West Africa died after catching Lassa fever, state officials said...
[2024/10/25] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
Heart Attack Model Suggests Therapeutic Role for Repair Protein GPNMB
UCLA scientists have identified a protein called glycoprotein nonmetastatic melanoma protein B (GPNMB) as a critical regulator in the heart’s healing process after a heart attack (myocardial infarction; MI). Using animal models, the team, co-led by UCLA professor of...
Prenatal Gene Therapy via LNPs Shows Promise in Model of Neurodevelopmental Disorder
The vehicles that deliver gene editing cargo to the body’s cells can be toxic, complicating gene therapies, particularly those addressed to brain cells of developing fetuses. Less toxic carriers, however, are being developed by scientists affiliated with the...
Lipin1 Inhibition Enhances Axon Regeneration: A Potential Therapeutic Approach for Spinal Cord Injury
Traumatic injuries to the central nervous system (CNS) often result in permanent functional deficits due to the limited capacity of CNS neurons to regenerate. Although advancements in spinal cord injury (SCI) research have been made, achieving substantial nerve fiber...
CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study
The promise of a one-and-done CRISPR infusion is beginning to look more real than ever. On Thursday, Intellia Therapeutics announced that an experimental gene editing therapy reduced dangerous and unpredictable swelling attacks caused by the disease hereditary...
Sangamo Therapeutics Secures Accelerated Approval Pathway for Gene Therapy in Fabry Disease
Sangamo Therapeutics has announced a major advancement in its gene therapy program for Fabry disease, as the U.S. FDA has provided a clear pathway for Accelerated Approval. This decision could potentially speed up approval timelines by three years, with a Biologics...
Focusing on Structural Changes May Be Key to AAV Separation
Separating full and empty adeno-associated virus (AAV) capsids during the manufacture of single-gene therapies remains a significant challenge. Ultracentrifugation and anion exchange chromatography (AEX) are common differentiation methods, but their success is,...
Orna Therapeutics Unveils Novel In Vivo Gene Editing Data Highlighting Engineering and Delivery Approach at the 31st Annual European Society of Gene & Cell Therapy Congress
--Lead type V editor program in SCD demonstrates industry leading delivery and repeat dosing with a passive LNP-- --Results reveal unprecedented improvement of editing rates from single digits to nearly 80% in primary HSPCs-- Orna Therapeutics, a biotechnology company...
Affinia Therapeutics to Highlight New Data on Genetic Cardiomyopathy Programs and BBB-Penetrant Capsids Leveraging Novel Receptors at the European Society of Gene & Cell Therapy 2024 31st Annual Congress
AFTX-201, Affinia's gene therapy program in BAG3 dilated cardiomyopathy, demonstrates efficacy, safety, and differentiation in a genetically relevant preclinical model, with full restoration of cardiac function Additional data show Affinia's gene therapy program in...
Popular Services
AAV Packaging Service
AAV Analytical Service
Vector Design